Alzheimer Disease Clinical Trial
— ENHANCEOfficial title:
Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders (ENHANCE)
The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are the following: 1. To compare the effectiveness of FAM-HELP and HELP in reducing both the incidence of delirium and its severity. 2. To compare the effectiveness of FAM-HELP and HELP in improving patient- and family-reported outcomes. 3. To explore the implementation context, process, and outcomes of the FAM-HELP program in diverse hospital settings.
Status | Recruiting |
Enrollment | 3000 |
Est. completion date | August 2027 |
Est. primary completion date | May 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 70 Years and older |
Eligibility | Inclusion Criteria: - Provision of informed consent - At least 70 years of age - Anticipated length of hospital stay at least 72 hours - Family member or care partner available to be on-site in the hospital - At least one delirium risk factor (e.g., cognitive or functional impairment, dehydration, vision or hearing impairment) Exclusion Criteria: - Delirium on admission - Unable to communicate verbally (e.g., coma, mechanical ventilation) - Unable to participate fully in interventions (e.g., terminal condition, advanced dementia) - Staff safety concerns (e.g., violent behavior) - Cardiac or intracranial surgery (due to competing causes of delirium) |
Country | Name | City | State |
---|---|---|---|
United States | Michigan Medicine | Ann Arbor | Michigan |
United States | Meriter Hospital | Madison | Wisconsin |
United States | Saddleback Medical Center | Orange | California |
United States | Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Allegheny General Hospital | Pittsburgh | Pennsylvania |
United States | MaineHealth | Portland | Maine |
United States | University of Utah | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
University of Michigan | Brandeis University, Hebrew SeniorLife, Indiana University, MaineHealth, MemorialCare Saddleback Medical Center, Patient-Centered Outcomes Research Institute, UnityPoint Health - Meriter Hospital, University of Pennsylvania, University of Utah, West Penn Allegheny Health System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Antipsychotic use | Proportion of participants in each group (%) requiring antipsychotic medications during hospitalization | Day of trial enrollment through day of hospital discharge, up to 14 days | |
Other | Restraint use | Proportion of participants in each group (%) requiring restraint use during hospitalization | Day of trial enrollment through day of hospital discharge, up to 14 days | |
Primary | Delirium Incidence | Any positive delirium screen (yes/no) as determined by the long-form Confusion Assessment Method (CAM) | Day of trial enrollment through day of hospital discharge, up to 14 days | |
Primary | Delirium Severity | Delirium severity score will be recorded using the Confusion Assessment Method Long Form Severity Score (CAM-S) (n, 0-19, with higher number indicating more severe delirium) | Day of trial enrollment through day of hospital discharge, up to 14 days | |
Secondary | Delirium Duration | The cumulative number of days (n) with a positive delirium screen will be calculated for all participants | Day of trial enrollment through day of hospital discharge, up to 14 days | |
Secondary | Persistent Delirium | Positive delirium screen (yes/no) 30 days after hospital discharge as determined by the long-form Confusion Assessment Method (AM) | 30 days after hospital discharge | |
Secondary | Delirium Burden - Patient | Delirium burden will be calculated using the Patient Delirium Burden Scale (DEL-B-P) (n, 0-40, with higher number indicating more severe burden) | Day of trial enrollment through 30 days after discharge | |
Secondary | Delirium Burden - Family and Care Partners | Delirium burden will be calculated using the Patient Delirium Family Caregiver Scale (DEL-B-C) (n, 0-40, with higher number indicating more severe burden) | Day of trial enrollment through 30 days after discharge | |
Secondary | Caregiving Strain | Strain associated with patient caregiving will be assessed via Modified Caregiver Strain Index (MCSI) (n, 0-26, with higher number indicating more caregiver strain) | Hospital discharge through 30 days after discharge | |
Secondary | Cognitive Function - Subjective Reporting | Subjective reporting of cognitive function will be assessed via PROMIS Cognitive Function - Short Form 6a (n, 6-30, with higher number indicating better subjective cognitive function) | Hospital discharge through 30 days after discharge | |
Secondary | Hospital Experience | Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey (n, 7-28, with higher score indicating better hospital experience) | Day of hospital discharge (typically up to 30 days after hospital admission, may extend to 60 or more days) | |
Secondary | Global Health | Assessment of overall physical and mental health via PROMIS Global Health-10. Two separate subscales will be calculated, Global Physical Health (n, 4-20) and Global Mental Health (n, 4-20), with higher scores indicating better health. | Hospital discharge through 30 days after discharge | |
Secondary | Physical Function | Assessment of physical function via PROMIS Physical Short Form 10a (n, 10-50, with higher scores indicating better physical function). | 30 days after hospital discharge | |
Secondary | Falls | Proportion of participants in each group (%) experiencing at least one fall | Day of trial enrollment through 30 days after hospital discharge | |
Secondary | Length of Hospital Stay | Total number of days (n) spent in the hospital | Day of hospital admission through hospital discharge (typically up to 30 days after hospital admission, may extend to 60 or more days) | |
Secondary | Discharge Disposition | Proportion of patients in each group (%) discharged somewhere other than home (e.g., Long-Term Care Facility) | Day of hospital discharge through 30 days after discharge | |
Secondary | 30-Day Readmission | Proportion of participants in each group (%) requiring hospital readmission | Day of hospital discharge through 30 days after discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |